Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Testing and Linkage to HIV Care in China (CTN 0056)

16. srpna 2016 aktualizováno: Walter Ling, University of California, Los Angeles

Testing and Linkage to HIV Care in China: A Clustered Randomized Trial

This study will evaluate the effects of a comprehensive approach (One4All) to increase the percentage of patients that receive their HIV testing results and counseling.

Primary Hypothesis: The One4All approach will increase the proportion of individuals who have completed all tests to confirm HIV diagnosis and received counseling within 30 days of screening HIV+, given they have screened HIV+ on the initial test, from 40% to 60%.

Přehled studie

Postavení

Dokončeno

Podmínky

Intervence / Léčba

Detailní popis

The study consists of a cluster randomized trial (CRT) at county hospitals in Guangxi, China to assess the effectiveness of a structural intervention: a new testing algorithm, consisting of rapid point-of-care (POC) HIV and CD4 testing, with viral load (VL) testing in parallel, designed to ensure completeness of diagnostic assessment and accelerate time to ART initiation for patients deemed ART eligible (hereafter called the One4all Test Intervention).

This CRT will be conducted in 12 county general hospitals with an estimated average of 30 participants per hospital, totaling an estimated 360 participants. The unit of randomization is the hospital. Hospitals will be randomized to 1) theOne4all Test Intervention, or 2) the control condition, consisting of the current standard of care (SOC). The efficacy of the intervention will be evaluated at 1, 3, and 12 month follow-up assessments, and the differential efficacy for drug users (DUs) and non-drug users will be examined.

The study population will consist of adult participants who screen positive on an initial HIV enzyme immunoassay (EIA) in the 12 study hospitals. Since the study will be conducted in China, the vast majority of participants will be of Chinese or Asian descent. Women will be included and are expected to represent approximately 26% of the study population.

Eligibility Criteria:

Site Eligibility Criteria: The location of our study is Guangxi Zhuang Autonomous Region (Guangxi). We will select county-level general hospitals in order to ensure sufficient caseload at each hospital and homogeneity across hospitals. Guangxi counties usually have one general hospital (a limited number of counties have two or more general hospitals); this hospital has been designated as the only setting for delivering ART services in the respective county.

Study hospitals (n=12) will be selected based on the number of reported HIV positive screenings in the first 6 months of the previous year (2012) and on homogeneity in testing procedures between hospitals. Selected hospitals will have reported at least 30 patients who screened positive during the period of January to June 2012. Should more than 12 hospitals be identified the lowest screen positive hospital will not be considered for participation.

Participant Eligibility Criteria: Inclusion criteria will be 1) age 18 or older, 2) seeking care in study hospitals, 3) local residency or intent to live in study area for at least 90 days, and 4) received HIV positive results on the initial screening test. Any patient who does not meet these inclusion criteria will be excluded from the study. Additionally, patients who are pregnant or who have previously received confirmation of HIV infection in other care settings (e.g. CDC clinic, infectious disease hospital, sub-county-level hospital) are not eligible to participate. Any patient who is a prisoner or detainee at the time of initial screening will be excluded from the study. In the event that a participant is enrolled at a study hospital and subsequently incarcerated, data will be collected.

Typ studie

Intervenční

Zápis (Aktuální)

360

Fáze

  • Fáze 2
  • Fáze 3

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní místa

  • Čína
    • Guangxi
      • Chongzu, Guangxi, Čína
        • Daxin County People's Hospital
      • Chongzuo, Guangxi, Čína
        • Fusui County People's Hospital
      • Chongzuo, Guangxi, Čína
        • Ningming County People's Hospital
      • Guilin, Guangxi, Čína
        • Lingui County People's Hospital
      • Guilin, Guangxi, Čína
        • Lipu County People's Hospital
      • Hechi, Guangxi, Čína
        • Duan County People's Hospital
      • Laibin, Guangxi, Čína
        • Xiangzhou County People's Hospital
      • Liuzhou, Guangxi, Čína
        • Rongan County People's Hospital
      • Nanning, Guangxi, Čína
        • Longan County People's Hospital
      • Qingzhou, Guangxi, Čína
        • Lingshan County People's Hospital
      • Wuzhou, Guangxi, Čína
        • Cenxi County People's Hospital
      • Yulin, Guangxi, Čína
        • Bobai County People's Hospital

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

18 let a starší (Dospělý, Starší dospělý)

Přijímá zdravé dobrovolníky

Ano

Pohlaví způsobilá ke studiu

Všechno

Popis

Inclusion Criteria:

Participating individuals must:

  1. Be at least 18 years old
  2. Be an inpatient or outpatient seeking care in study hospitals
  3. Test positive on an initial EIA HIV screen
  4. Have local residency or intent to live in study area for at least 90 days

Exclusion Criteria:

Individuals will be excluded from study participation if they:

  1. Do not meet any one or more of the above inclusion criteria
  2. Test result negative on initial EIA HIV screen
  3. Have previously received confirmation on HIV infection in the study hospital or in any other setting (e.g., CDC clinic, infectious disease hospital, sub-county-level hospital)
  4. Are prisoners or detainees at the time of initial screening
  5. Are pregnant women (pregnant women are subject to mandatory testing)

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Primární účel: Léčba
  • Přidělení: Randomizované
  • Intervenční model: Paralelní přiřazení
  • Maskování: Žádné (otevřený štítek)

Zbraně a zásahy

Skupina účastníků / Arm
Intervence / Léčba
Experimentální: One4All
Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
Behaviorální: One4All
Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
Aktivní komparátor: Standard of Care

The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.

After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.

Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling.
Behaviorální: Standard of Care

The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.

After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.

Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling.

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Receipt of post-test results and counseling following testing completeness
Časové okno: 30 days
The numerator is the number of HIV-positive participants who have received post-test results and counseling within 30 days of initial screening blood draw. The denominator is the number of participants who screened positive on the initial HIV EIA in the study arm (control or intervention).
30 days

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Proportion of treatment-eligible participants with CD4 < 350
Časové okno: 90 days
A secondary outcome is the proportion of treatment-eligible participants with CD4< 350 cells/mm3 who have initiated ART within 90 days of an initial positive HIV screening. We will define the secondary endpoint variable for hypothesis as a binary variable. If a participant with CD4 <350 cells/mm3 initiates ART within 90 days of a positive screening, the variable is defined equal to one. Otherwise, the variable is defined equal to zero. All participants who screened HIV-positive on the initial EIA at screening will be included in the analysis.
90 days

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
Proportion of participants who have viral suppression based on the 12-month viral load test.
Časové okno: 12 months
A tertiary outcome is the proportion of participants who have viral suppression based on the 12-month viral load test, where viral suppression is defined as viral load < 200 copies/mL We will define the tertiary endpoint variable as a binary variable. If a participant with VL < 200 copies/mL at 12 months after initial screening, the variable is defined equal to one. Otherwise, the variable is defined equal to zero. All participants who screened HIV-positive on the initial EIA at screening will be included in the analysis.
12 months

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Sponzor

University of California, Los Angeles

Spolupracovníci

National Institute on Drug Abuse (NIDA)

Vyšetřovatelé

  • Vrchní vyšetřovatel: Walter Ling, MD, University of California, Los Angeles
  • Vrchní vyšetřovatel: Zunyou Wu, MD, PhD, National Center for AIDS/STD control and prevention
  • Vrchní vyšetřovatel: Roger Detels, MD, MS, University of California, Los Angeles

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Obecné publikace

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia

1. března 2014

Primární dokončení (Aktuální)

1. srpna 2014

Dokončení studie (Aktuální)

1. ledna 2016

Termíny zápisu do studia

První předloženo

7. března 2014

První předloženo, které splnilo kritéria kontroly kvality

7. března 2014

První zveřejněno (Odhad)

11. března 2014

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Odhad)

18. srpna 2016

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

16. srpna 2016

Naposledy ověřeno

1. ledna 2016

Více informací

Termíny související s touto studií

Klíčová slova

Další identifikační čísla studie

  • NIDA CTN 0056
  • U10DA013045 (Grant/smlouva NIH USA)

Plán pro data jednotlivých účastníků (IPD)

Studijní data/dokumenty

  1. Protokol studie
    Identifikátor informace: CTN0056

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Klinické studie na HIV

Prohledejte podobné pokusy

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

CROs by country

CROs in Thailand

Podmínky

Vzácné nemoci

Drogové intervence

Doplňky stravy

Sponzor / Spolupracovníci

Místa

3
Předplatit